Tesamorelin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Doak Barnett, who had travelled extensively in Xikang during the late 1940s, opined in 1993 that Liu's rule had been "one of the most oppressive and one of the worst warlord regimes in China." Academically, Western literature and scholarship treats Liu as a structural actor of Chinese frontier administration under pressure. To historian Joe Lawson, Liu's rule represents an evolution—not a break—of prior Qing-era ruler Zhao Erfeng's methods, influenced by pressures such as the political fragmentation of the Republican era. Another historian, James Leibold, frames Liu's domain as a "parasitic polity" within the larger Chinese state, a peripheral nuisance that disrupted the Nanjing government's attempts at centralization. Leibold also mentions Liu's adoption by the PRC's historiography, influenced by his defection to the communist side, that frames him in heroic terms as a frontier developer, a protector of minority groups, and an anti-imperialist. Here, the unsavory aspects of Liu's rule, especially the more colonial-esque measures, are attributed to Chiang Kai-shek. By September 2025, Liu Wenhui's former residence in Chengdu had become a museum. In January 2019, it was designated a party history education base by the Revolutionary Committee of the Chinese Kuomintang. Liu's residence has also been designated as a national priority protected site.
===== Morphology change ===== As shown by flow cytometry and electron microscopy, the most sensitive sign of activation, when exposed to platelets using ADP, are morphological changes. Mitochondrial hyperpolarization is a key event in initiating morphology changes. Intraplatelet calcium concentration increases, stimulating the interplay between the microtubule/actin filament complex. The continuous changes in shape from the unactivated to the fully activated platelet are best seen via scanning electron microscopy. The three steps along this path are named early dendritic, early spread, and spread. The surface of the unactivated platelet looks similar to the surface of the brain–a wrinkled appearance from numerous shallow folds that increase the surface area; early dendritic, an octopus with multiple arms and legs; early spread, an uncooked frying egg in a pan, the "yolk" is the central body; and the spread, a cooked fried egg with a denser central body. These changes are all brought about by the interaction of the microtubule/actin complex with the platelet cell membrane and open canalicular system (OCS), which is an extension and invagination of that membrane. This complex runs just beneath these membranes and is the chemical motor that pulls the invaginated OCS out of the interior of the platelet, like turning pants pockets inside out, creating the dendrites. This process is similar to the mechanism of contraction in a muscle cell. The entire OCS thus becomes indistinguishable from the initial platelet membrane as it forms the "fried egg".
=== Three dimensional artifacts === Three-dimensional artifacts that have been damaged often require Full backings, but are difficult to apply to three-dimensional textiles. Tailoring techniques such as darts, gathering, similar to original construction techniques can be employed to create shaped backings or supports Occasionally, disassembly is permitted for three-dimensional materials. Shaped forms are also sometimes used as supports. When textiles are used in three-dimensional structures such as covered boxes and upholstered furniture are damaged an overlay can be stitched into lower layers. A less invasive treatment option is passive support. Conditions for use of passive supports: - no major structural damages (tears or holes) - The ground fabric must be intact. - Ideally the textile on its original strainer. - Requires protection against puncture. - Supplementary supports help in limit damages as a result of vibration, shock, and flexing. - The fabric requires additional protection because it is sagging on the strainer. - In the event that the textile has never been removed from its original strainer. The below techniques must be modified to accommodate original lacing: A padded insert provides passive protection. A padded, fabric-covered insert should be created specifically for the object to fill the strainer. Polyester felt or batting can be utilized for a precise fit. A rigid backing (archival-quality rag board of appropriate thickness/rigidity), should be affixed to the insert by thread ties, sewing, or adhesives is used to keep the padded insert secure.
Sources: en.wikipedia.org
== Measured variables and units == In principle, reducing the exposure of the human organism to ionizing radiation to zero is not possible and perhaps not even sensible. The human organism has been accustomed to natural radioactivity for thousands of years and ultimately this also triggers mutations (changes in genetic material), which are the cause of the development of life on earth. The mutation-inducing effect of high-energy radiation was first demonstrated in 1927 by Hermann Joseph Muller (1890-1967). Three years after its establishment in 1958, the United Nations Scientific Committee on the Effects of Atomic Radiation adopted the Linear No-Threshold (LNT) model - a linear dose-effect relationship without a threshold - largely at the instigation of the Soviet Union. The dose-response relationship measured at high doses was extrapolated linearly to low doses. There would be no threshold, since even the smallest amounts of ionizing radiation would trigger some biological effect. The LNT model ignores not only possible radiation hormesis, but also the known ability of cells to repair genetic damage and the ability of the organism to remove damaged cells. Between 1963 and 1969, John W. Gofman (1918-2007) and Arthur R. Tamplin of the University of California, Berkeley, conducted research for the United States Atomic Energy Commission (USAEC, 1946-1974) investigating the relationship between radiation doses and cancer incidence. Their findings sparked a fierce controversy in the United States beginning in 1969. Starting in 1970, Ernest J.
=== Inhibition of ACTH production === Corticotropes contain glucocorticoid receptors (GRs) and corticosteroid-binding globulin (CBG, or transcortin). GR is a nuclear receptor that inhibits transcription of ACTH via a negative glucocorticoid recognition element (GRE) that binds cortisol on POMC DNA, but generally transcortin binds glucocorticoids (including cortisol, cortisone, deoxycortisone, and aldosterone) with high affinity and prevents this inhibition. Tonic inhibition of corticotropes requires high concentrations of glucocorticoids, exceeding CBG capacity. This causes ACTH secretion to be vulnerable to inhibition in patients taking glucocorticoids for medical purposes such as treatment of autoimmune disease or as an anti-transplant-rejection medication.
Alginic acid (E400), sodium alginate (E401), potassium alginate (E402), ammonium alginate (E403), calcium alginate (E404) - polysaccharides from brown algae Agar (E406, a polysaccharide obtained from red algae) Carrageenan (E407, a polysaccharide obtained from red seaweeds) Locust bean gum (E410, a natural gum polysaccharide from the seeds of the carob tree) Pectin (E440, a polysaccharide obtained from apple or citrus-fruit) Gelatin (E441, made by partial hydrolysis of animal collagen) Commercial jellies used in East Asian cuisines include the glucomannan polysaccharide gum used to make "lychee cups" from the konjac plants, and aiyu or ice jelly from the Ficus pumila climbing fig plant. Agar-agar produces a very clear gel with light residual taste. Gelatin sheets disperse easily with no residual taste, but powdered form may have some taste. Kappa carrageenan may include potassium chloride to improve the gelling process and produces a clear product with very little aftertaste. Iota carrageenan contains sodium chloride which improves gel formation. Sodium alginate produces a medium viscosity gel but may have some aftertaste. High-methoxy pectin is one of the most widely used gelling agents in food processing. It reacts with some sugars and acids and sometimes includes minerals to improve gelling process. Low-methoxy pectin reacts with calcium, and is used for the preparation of low sugar jams.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.